top of page
Overview

Overview

adlib from email.png

COVID-19 Health Declaration

INTRODUCTION

As part of our COVID safety management, we have engaged in a risk assessment process looking at possible control measures for specific tasks, travel and adopting current government guidance and requirements. One of our control measures identified in our COVID-19 risk assessment is to ensure anyone working for us, either at Adlib House or on external sites are not showing symptoms of COVID-19, have not been in contact with anyone showing symptoms and will alert their key contact or manager immediately if any symptoms begin to show.

​

In addition to staff members, any third party contractor, visitor or driver/logistics operator must also provide assurances of symptoms, as well as confirmation of their own company health monitoring arrangements. 

​

​

ABOUT THE DECLARATION

This declaration will outline key symptoms of COVID-19 and ask you to confirm you are not showing any of these, nor anyone in your household. In addition, if you are classed as high risk (previously referred to as clinically extremely vulnerable) person you should declare this in the relevant question. If you are unsure, please click here.

​

This declaration will also ask you to confirm that you agree to your details being submitted and held by this system. 

​

Your details are held securely for the purpose of the health declaration only. Your details will not be shared with anyone outside of Adlib or ESS. 

 

If you have any concerns, please discuss either your main contact directly or our office info@ess-consultants.co.uk.

 

To continue with the declaration, please select the button below. 

​

​

​

AD CEVP

CLINICALLY EXTREMELY VULNERABLE PEOPLE

Clinically extremely vulnerable people may include the following people. Disease severity, history or treatment levels will also affect who is in this group.

  1. Solid organ transplant recipients.

  2. People with specific cancers:

    • people with cancer who are undergoing active chemotherapy

    • people with lung cancer who are undergoing radical radiotherapy

    • people with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment

    • people having immunotherapy or other continuing antibody treatments for cancer

    • people having other targeted cancer treatments which can affect the immune system, such as protein kinase inhibitors or PARP inhibitors

    • people who have had bone marrow or stem cell transplants in the last 6 months, or who are still taking immunosuppression drugs

  3. People with severe respiratory conditions including all cystic fibrosis, severe asthma and severe chronic obstructive pulmonary (COPD).

  4. People with rare diseases that significantly increase the risk of infections (such as severe combined immunodeficiency (SCID), homozygous sickle cell).

  5. People on immunosuppression therapies sufficient to significantly increase risk of infection.

  6. Women who are pregnant with significant heart disease, congenital or acquired.

People in this group should have been contacted to tell them they are clinically extremely vulnerable.

If you are still concerned, you should discuss your concerns with your GP or hospital clinician.

bottom of page